- 1.
Holman RR, Haffner SM, McMurray JJ et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1463 – 76.
- 2.
McMurray JJ, Holman RR, Haffner SM et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1477 – 90.
- 3.
Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle interventions or metformin. N Engl J Med 2002; 346: 393 – 403.
- 4.
Chiasson JL, Josse RG, Gomis R et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072 – 7.
- 5.
Gerstein HC, Yusuf S, Bosch J et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096 – 105. Erratum i: Lancet 2006; 368: 1770.
- 6.
Holman RR, Paul SK, Bethel MA et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359: 1565 – 76.
- 7.
Sartor G, Scherstén B, Carlström S et al. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980; 29: 41 – 9.
- 8.
Keen H, Jarrett RJ, McCartney P. The ten-year follow-up of the Bedford survey (1962 – 1972): glucose tolerance and diabetes. Diabetologia 1982; 22: 73 – 8.
- 9.
Karunkaran S, Hammersley MS, Morris RJ et al. The Fasting Hyperglycemia Study: III. Randomized control trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose. Metabolism 1997; 46 (suppl 1): 56 – 60.
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.